Core Viewpoint - Ardelyx Inc. reported a breakeven performance for Q4 2025, with sales of $125.22 million, surpassing the consensus estimate of $118.13 million [1] Revenue Performance - IBSRELA (tenapanor) revenue grew 73% in 2025 to $274.2 million, contributing to total revenues of $407.3 million; Q4 revenue for IBSRELA was $86.6 million, up 61% year over year [2] - XPHOZAH (tenapanor) revenue in 2025 was $103.6 million, with Q4 revenue of $27.8 million; expected 2026 revenue for XPHOZAH is projected between $110 million and $120 million [4] Growth Expectations - Ardelyx anticipates full-year 2026 revenue for IBSRELA to be between $410 million and $430 million, indicating at least 50% growth compared to 2025 [2] - The company expects IBSRELA to achieve $1 billion in annual revenue by 2029, with further growth anticipated thereafter [3] Pipeline Developments - Ardelyx plans to submit a Supplemental New Drug Application to the FDA for the CIC indication, pending Phase 3 trial outcomes; enrollment in the ACCEL trial is expected to complete by the end of 2026 [5] - A development program for RDX10531, a next-generation sodium/hydrogen exchanger 3 (NHE3) inhibitor, is underway, with an Investigational New Drug submission planned for the second half of 2026 [6] Technical Analysis - Ardelyx shares are currently trading 17.6% below the 20-day simple moving average (SMA) and just 0.1% below the 100-day SMA, indicating short-term weakness [7] - The stock has increased 17.83% over the past 12 months and is closer to its 52-week highs than lows [7] Analyst Consensus - The stock carries a Buy Rating with an average price target of $12.86; recent analyst actions include maintaining a Buy rating with a target of $17.00 and raising the target to $19.00 [10]

Core Insights - Ardelyx, Inc. is participating in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025 [1] - The company focuses on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs [3] Company Overview - Ardelyx has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - The company is developing RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas [3] - Ardelyx has international agreements for the commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3]

Core Insights - Ardelyx, Inc. is focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs [3] Company Overview - Ardelyx has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - The company is developing RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3] Upcoming Events - The President and CEO of Ardelyx, Mike Raab, will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on November 10, 2025 [1] - A public webcast of the event will be available on the Ardelyx website, with a replay accessible for 30 days post-event [2]

Core Insights - Ardelyx, Inc. reported Q3 2025 product revenue of $105.5 million, reflecting a 15% year-over-year growth, driven primarily by strong performance from IBSRELA and XPHOZAH [1][2][13] - IBSRELA revenue reached $78.2 million in Q3 2025, marking a 92% increase year-over-year and a 20% increase compared to Q2 2025, with full-year 2025 revenue guidance raised to between $270-275 million [1][4][13] - XPHOZAH generated $27.4 million in revenue during Q3 2025, up 9% from Q2 2025, supported by increased demand and effective commercial strategies [1][5][13] - The company announced the development of RDX10531, a next-generation NHE3 inhibitor, which is expected to have applications across multiple therapeutic areas [1][6][21] Financial Performance - Total revenue for Q3 2025 was $110.3 million, compared to $98.2 million in Q3 2024, primarily due to increased IBSRELA revenue, despite a decline in XPHOZAH revenue [13][28] - Research and development expenses for Q3 2025 were $18.1 million, up from $15.3 million in Q3 2024, while selling, general and administrative expenses increased to $83.6 million from $65.0 million [13][28] - The net loss for Q3 2025 was $1.0 million, or $(0.00) per share, compared to a net loss of $0.8 million, or $(0.00) per share, in Q3 2024 [13][28] Corporate Developments - Ardelyx appointed Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025, and announced other key appointments in August 2025 [7] - The company had a significant presence at the 2025 Annual Scientific Meeting for the American College of Gastroenterology, showcasing its commitment to advancing medical knowledge and product visibility [8]